Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.

Purpose: To investigate early diffusion-weighted imaging (DWI) at 30-days post-yttrium-90 (Y-90) radioembolization as a predictor of treatment response and survival in unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).Materials and Methods: In a prospective s...

Descripción completa

Detalles Bibliográficos
Publicado en:Abdominal Imaging Vol. 39; no. 5; pp. 969 - 979
Autores principales: Kokabi, Nima, Camacho, Juan C, Xing, Minzhi, Qiu, Deqiang, Kitajima, Hiroumi, Mittal, Pardeep K, Kim, Hyun S
Formato: research Journal Article
Publicado: Springer Nature Oct2014
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109755884&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 109755884
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09428925
        O52
      jtl: Abdominal Imaging
      issn: 09428925
      maglogo: N
    pubinfo:
      dt: Oct2014
      vid: 39
      iid: 5
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        109755884
        NLM24740759
        2012735313
        10.1007/s00261-014-0127-8
        NLM24740759
        109755884
      ppf: 969
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
      aug:
        au:
          Kokabi, Nima
          Camacho, Juan C
          Xing, Minzhi
          Qiu, Deqiang
          Kitajima, Hiroumi
          Mittal, Pardeep K
          Kim, Hyun S
        affil: Division of Interventional Radiology & Image Guided Medicine, Department of Radiology, Emory University School of Medicine, Suite AG05, 1364 Clifton Road, NE, Atlanta, GA, 30322, USA, nkokabi@emory.edu.
      sug:
        subj:
          Carcinoma, Hepatocellular Radiotherapy
          Magnetic Resonance Imaging Methods
          Embolization, Therapeutic Methods
          Liver Neoplasms Radiotherapy
          Venous Thrombosis Radiotherapy
          Radioisotopes Therapeutic Use
          Carcinoma, Hepatocellular Complications
          Female
          Human
          Liver Neoplasms Complications
          Male
          Middle Age
          Portal Vein
          Predictive Value of Tests
          Prospective Studies
          Radiopharmaceuticals Therapeutic Use
          Survival Analysis
          Treatment Outcomes
          Venous Thrombosis Complications
          Middle Aged: 45-64 years
          Female
          Male
      ab: Purpose: To investigate early diffusion-weighted imaging (DWI) at 30-days post-yttrium-90 (Y-90) radioembolization as a predictor of treatment response and survival in unresectable infiltrative hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT).Materials and Methods: In a prospective study, 18 consecutive patients with unresectable infiltrative HCC and PVT underwent Y-90 therapy. MR imaging was obtained pre Y-90, and at 1 and 3 months post-therapy with DWI fat-suppressed tri-directional diffusion gradient (b = 50, 400, 800 s/mm(2)). Response was evaluated using target mRECIST and EASL. Relative change in apparent diffusion coefficient (ADC) value of tumors was evaluated. Statistical analysis using receiver operator characteristic curves was performed. Paired t test and Pearson correlation coefficient (r) were used to assess intra- and inter-observer variability. Survival analysis was performed using Kaplan-Meier estimation and log-rank test.Results: Mean ADC values of all HCC's at baseline and at 30-days post-Y90 therapy was 0.86 × 10(-3) and 1.17×10(-3) mm(2)/s, respectively (p < 0.001). Tumors with objective response by mRECIST had significantly increased ADC value when compared to "non-responders" (1.27 vs. 1.05×10(-3) mm(2)/s, p = 0.002). A >30% increase in ADC value at 30-days was found to be at least 90% sensitive in predicting response at 90 days. A >30% increase in ADC value at 30-days predicted significantly prolonged survival.Conclusion: A 30% increase in ADC value at 30-days measured post Y90 is a reproducible early imaging response biomarker predicting tumor response and prolonged survival following Y-90 therapy in infiltrative HCC with PVT.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N